Intestinal Disease
4
Pipeline Programs
3
Companies
3
Clinical Trials
1 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
2
2
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
3 companies ranked by most advanced pipeline stage
Pharmbio KoreaKorea - Seoul
2 programs2
PBK_M2101 2-DayPhase 31 trial
PBK_M2502 1-DayPhase 31 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2023
2024
2025
2026
MSDNeostigmine Injectable Solution
Pharmbio KoreaPBK_M2502 1-Day
Pharmbio KoreaPBK_M2101 2-Day
Clinical Trials (3)
Total enrollment: 484 patients across 3 trials
Neuromuscular Blockade Comparison for GI-2 Recovery After Bowel Resection
Start: Apr 2024Est. completion: Jul 2026128 patients
Phase 4Recruiting
A Study to Evaluate Safety and Efficacy of PBK_M2502
Start: Aug 2025Est. completion: Nov 2026110 patients
Phase 3Not Yet Recruiting
A Study to Evaluate Safety and Efficacy of PBK_M2101
Start: Jun 2023Est. completion: Jun 2024246 patients
Phase 3Unknown
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
2 late-stage (Phase 3) programs, potential near-term approvals
1 actively recruiting trials targeting 484 patients
3 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.